CN107347998A - A kind of baby milk powder for strengthening nutrient absorption and immunity of organisms and preparation method thereof - Google Patents
A kind of baby milk powder for strengthening nutrient absorption and immunity of organisms and preparation method thereof Download PDFInfo
- Publication number
- CN107347998A CN107347998A CN201710687015.3A CN201710687015A CN107347998A CN 107347998 A CN107347998 A CN 107347998A CN 201710687015 A CN201710687015 A CN 201710687015A CN 107347998 A CN107347998 A CN 107347998A
- Authority
- CN
- China
- Prior art keywords
- lactose
- base
- milk
- parts
- sugared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 85
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 55
- 230000036039 immunity Effects 0.000 title claims abstract description 31
- 235000015816 nutrient absorption Nutrition 0.000 title claims abstract description 27
- 238000005728 strengthening Methods 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 58
- 235000013336 milk Nutrition 0.000 claims abstract description 55
- 210000004080 milk Anatomy 0.000 claims abstract description 55
- 239000008267 milk Substances 0.000 claims abstract description 55
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 42
- 235000020256 human milk Nutrition 0.000 claims abstract description 42
- 210000004251 human milk Anatomy 0.000 claims abstract description 42
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 39
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 38
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 38
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 32
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 32
- 235000019742 Vitamins premix Nutrition 0.000 claims abstract description 29
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 28
- 239000008101 lactose Substances 0.000 claims abstract description 28
- 241001494479 Pecora Species 0.000 claims abstract description 27
- 235000021119 whey protein Nutrition 0.000 claims abstract description 25
- 102000009027 Albumins Human genes 0.000 claims abstract description 23
- 108010088751 Albumins Proteins 0.000 claims abstract description 23
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract description 20
- 229940114079 arachidonic acid Drugs 0.000 claims abstract description 19
- 235000021342 arachidonic acid Nutrition 0.000 claims abstract description 19
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 19
- 235000010755 mineral Nutrition 0.000 claims abstract description 19
- 239000011707 mineral Substances 0.000 claims abstract description 19
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 19
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 18
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 18
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000005642 Oleic acid Substances 0.000 claims abstract description 18
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 18
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 16
- 150000002148 esters Chemical class 0.000 claims abstract description 16
- 235000021314 Palmitic acid Nutrition 0.000 claims abstract description 15
- 239000005862 Whey Substances 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 11
- 239000002131 composite material Substances 0.000 claims abstract description 9
- 239000002773 nucleotide Substances 0.000 claims abstract description 9
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 9
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 8
- 239000010773 plant oil Substances 0.000 claims abstract description 8
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 8
- 241000195493 Cryptophyta Species 0.000 claims description 79
- 239000011435 rock Substances 0.000 claims description 79
- 239000000463 material Substances 0.000 claims description 45
- 210000003296 saliva Anatomy 0.000 claims description 34
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 230000002708 enhancing effect Effects 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 claims description 12
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 claims description 12
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 claims description 12
- 229960003080 taurine Drugs 0.000 claims description 10
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 9
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000001694 spray drying Methods 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 6
- 239000004519 grease Substances 0.000 claims description 6
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 claims description 6
- 229940062780 lacto-n-neotetraose Drugs 0.000 claims description 6
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 239000011552 falling film Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000011155 wood-plastic composite Substances 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 102000004407 Lactalbumin Human genes 0.000 claims description 3
- 108090000942 Lactalbumin Proteins 0.000 claims description 3
- 230000021736 acetylation Effects 0.000 claims description 3
- 238000006640 acetylation reaction Methods 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000005194 fractionation Methods 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims description 3
- -1 lactose amine Chemical class 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 150000003538 tetroses Chemical class 0.000 claims description 3
- 238000007580 dry-mixing Methods 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 abstract description 7
- 230000007413 intestinal health Effects 0.000 abstract description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 abstract description 3
- 238000012545 processing Methods 0.000 abstract description 3
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 description 30
- 241000700159 Rattus Species 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 12
- 239000011575 calcium Substances 0.000 description 12
- 229910052791 calcium Inorganic materials 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 235000015097 nutrients Nutrition 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 8
- 235000019621 digestibility Nutrition 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 210000002175 goblet cell Anatomy 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 3
- 235000019743 Choline chloride Nutrition 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 235000019750 Crude protein Nutrition 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 3
- 229960003178 choline chloride Drugs 0.000 description 3
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 3
- 235000019784 crude fat Nutrition 0.000 description 3
- 229960002104 cyanocobalamin Drugs 0.000 description 3
- 235000000639 cyanocobalamin Nutrition 0.000 description 3
- 239000011666 cyanocobalamin Substances 0.000 description 3
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000011790 ferrous sulphate Substances 0.000 description 3
- 235000003891 ferrous sulphate Nutrition 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 229940099596 manganese sulfate Drugs 0.000 description 3
- 239000011702 manganese sulphate Substances 0.000 description 3
- 235000007079 manganese sulphate Nutrition 0.000 description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 230000000050 nutritive effect Effects 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000011781 sodium selenite Substances 0.000 description 3
- 235000015921 sodium selenite Nutrition 0.000 description 3
- 229960001471 sodium selenite Drugs 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 229940078499 tricalcium phosphate Drugs 0.000 description 3
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 3
- 235000019731 tricalcium phosphate Nutrition 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- 235000005282 vitamin D3 Nutrition 0.000 description 3
- 239000011647 vitamin D3 Substances 0.000 description 3
- 229940021056 vitamin d3 Drugs 0.000 description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 3
- 229960001763 zinc sulfate Drugs 0.000 description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 description 3
- 241000233788 Arecaceae Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000004493 neutrocyte Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 229960000344 thiamine hydrochloride Drugs 0.000 description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 2
- 239000011747 thiamine hydrochloride Substances 0.000 description 2
- WNCAVNGLACHSRZ-KAMYIIQDSA-N Allithiamine Chemical compound C=CCSSC(/CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N WNCAVNGLACHSRZ-KAMYIIQDSA-N 0.000 description 1
- WNCAVNGLACHSRZ-UHFFFAOYSA-N Allithiamine Natural products C=CCSSC(CCO)=C(C)N(C=O)CC1=CN=C(C)N=C1N WNCAVNGLACHSRZ-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- GLCGEJFIZRSXBL-UHFFFAOYSA-N dodeca-1,3,5,7,9,11-hexaene Chemical compound C=CC=CC=CC=CC=CC=C GLCGEJFIZRSXBL-UHFFFAOYSA-N 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000006919 peptide aggregation Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/04—Whey; Whey preparations containing non-milk components as source of fats or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/06—Mixtures of whey with milk products or milk components
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/08—Whey; Whey preparations containing other organic additives, e.g. vegetable or animal products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/10—Whey; Whey preparations containing inorganic additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a kind of baby milk powder for strengthening nutrient absorption and immunity of organisms, raw material includes following components:Lactose, desalted whey powder, skimmed milk power, composite plant oil, the ester of 1,3 2 oleic acid, 2 palmitic acid three, WPC, milk albumin peptide or sheep whey protein peptide, mineral substance premix, arachidonic acid, human milk oligosaccharides, soybean lecithin, docosahexaenoic acid, water soluble vitamin premix, nucleotides, liposoluble vitamin premix etc..Using milk powder obtained by the present invention, effect is:Added while the ester of 1,3 two oleic acid, 2 palmitic acid three, human milk oligosaccharides and milk albumin peptide or sheep whey protein peptide, play synergy, can promote to digest and assimilate nutriment, healthy intestinal health, while improve immunity.Invention additionally discloses a kind of preparation method of above-mentioned milk powder, using the method disclosed in the present, effect is:Processing step is simplified, and technological parameter is easily controlled, and is adapted to large-scale production.
Description
Technical field
The present invention relates to field of food, and in particular to a kind of baby milk powder for strengthening nutrient absorption and immunity of organisms and
Its preparation method.
Background technology
Breast milk is the food for being best suitable for infant nutrient demand, but because a variety of causes, many mothers cannot be guaranteed breast milk
Abundance is fed, it is necessary to be fed using baby formula milk powder.
Although the existing dispensed food for baby of in the market is the milk after adding nutrient again as base-material using ox, sheep breast more
Powder, can be that the nutrition for providing abundance of the infant of different phase ensures.But contain abundant albumen in ripe breast milk
Matter, structuring fatty (containing a high proportion of Sn-2 palmitic acids Structure grease), mineral matter, vitamin, carbohydrate (mainly contain
Lactose and abundant oligosaccharide) etc..
Modern nutriology is relatively generally acknowledged, and breast milk is the optimal food of infant, and baby humanized milk powder
Golden standard.Can be with digestive some enzymes and immune protein and peptides in breast milk but can not cover in baby milk powder
Etc. the beneficiating ingredient for being beneficial to intestinal beneficial bacterium.Found by research:Human milk oligosaccharides (HMO) in human milk contain in people's colostrum
Measure and be:22-23g/L, during maturation is newborn:12-13g/L, the addition of human milk oligosaccharides, makes baby formula milk powder be more nearly mother
Breast.
The ester (structured lipid OPO) of 1,3 two oleic acid 2- palmitic acids three is actually a kind of structuring fat, passes through enzyme process
Ester-exchange technology simulates breast milk lipid molecular structure, 2 palmitate ratios is up to 40-50%, horizontal closer to breast milk, addition
Structured lipid OPO, lipid nutrition ingredient draws can be promoted, improve energy utilization and reduce constipation.And in mammal
Anatomical research during find that its distal small intestine has substantial amounts of small peptide aggregation, the experiment of continuation shows, mammal absorbs
The form of protein is mainly to be absorbed with small peptide.Small intestine is exactly the main absorption place of small peptide, turning for peptide on intestinal mucosa be present
Carrier, have transhipment fast, power consumption is low, the characteristics of being not easy saturation.The milk albumin peptide or sheep whey protein peptide of addition, can promote
Enter the absorption of protein.
Therefore, a kind of baby that constipation and the beneficiating ingredient that nutrient absorption can be strengthened can be reduced to antibacterium, and can is designed
Baby formulas milk powder is significant.
The content of the invention
The first object of the present invention, which is to provide one kind, to be included human milk oligosaccharides, structuring fat OPO and peptides etc. and has
The enhancing nutrient absorption of beneficial composition and the baby milk powder of immunity of organisms, concrete technical scheme are as follows:
A kind of baby milk powder for strengthening nutrient absorption and immunity of organisms, raw material is included with the following group in terms of parts by weight
Point:Lactose 25-33 parts, desalted whey powder 15-20 parts, skimmed milk power 12-37 parts, composite plant oil 16-27 parts, 1,3 2 oleic acid
The ester 2.4-9.6 parts of 2- palmitic acids three, WPC 5-9 parts, galactooligosaccharide 0-6 parts, FOS 0-6 parts, ox
Whey protein peptide or sheep whey protein peptide 0.01-0.3 parts, mineral substance premix 0.8-1.5 parts, arachidonic acid 0.3-1.8 parts,
Human milk oligosaccharides 0.1-2.5 parts, soybean lecithin 0.2-1.2 parts, docosahexaenoic acid 0.2-1.0 parts, water soluble vitamin are pre-
Batch mixing 0.1-0.4 parts, nucleotides 0.018-0.05 parts, liposoluble vitamin premix 0.01-0.06 parts, taurine 0.01-
0.04 part and l-cn 0.01-0.02 parts;
Each component parts by weight sum is 100 parts.
Preferable in above technical scheme, the human milk oligosaccharides are 2'- rock algae bases lactose, 3- rock algae bases lactose, 3'- salivas
Liquid lactose, 3'- saliva base-N- acetyl lactosamines, 6'- salivas lactose, 6'- saliva base-N- acetylation lactose amine, 3'- salivas base-
3- rock algae bases lactose, two sialyllactoses, single rock algae base, single saliva base lactose, lactose-N- trisaccharides, lacto-N-tetraose, lactose-
The new tetroses of N-, saliva base lacto-N-tetraose a, saliva base lacto-N-tetraose b, saliva base lacto-N-tetraose c, saliva base lactose-
N- tetroses d, double saliva base lacto-N-tetraoses, lactose-bis- rocks algae tetrose, single saliva base, single rock algae base lacto-N-tetraose, single saliva
Liquid-based, single rock algae base lacto-N-neotetraose, three rock algae base lacto-N-neotetraose I, lactose-N- rock algae pentasaccharides I, lactose-N- rocks
Algae pentasaccharides II, lactose-N- rock algae pentasaccharides III, lactose-N- rock algae pentasaccharides VI, lactose-N- rock algae pentasaccharides V, saliva base-lactose-N-
Rock algae pentasaccharides V, the new rock algae pentasaccharides I of lactose-N-, lactose-N- six be sugared, the sugar of p- lactose-N- six, new six sugar of lactose-N-, rock algae base-
P- lactose-N- six is sugared, double rock algae base-p- lactose-N- six are sugared, single sugared, single rock algae base lactose-N- of saliva base-lactose-N- new six
Six sugared, single six sugared I of rock algae base lactose-N-, single six sugared III of rock algae base lactose-N-, double six sugared a of rock algae base lactose-N-, double rock algaes
Six sugared b of base lactose-N-, double six sugared c of rock algae base lactose-N-, sugared, the double rock algae base lactose-N- new six of double rock algae base lactose-N- new six
Sugared b, double rock algae base-p- lactose-N- six be sugared, single saliva base, and double new six sugared, double rock algae base-p- lactose of rock algae base lactose-N--
New six sugar of N-, the sugar of three rock algae base lactose-N- six, the sugar of three rock algae bases-p- lactose-N- six, two rock algaes of lactose-N-, six sugared I, lactose-
The new new double rock algae bases six of the sugar of double rock algae bases six, lactose-N- of bis- rock algaes of N-, six sugared II, two rock algaes of lactose-N-, six sugared IV, lactose-N-
At least one of new six sugar of sugared II, p- lactose-N-, new ten sugar of lactose-N- and three rock algae bases-sugar of iso- lactose-N- ten.
Preferable in above technical scheme, content of the human milk oligosaccharides in milk powder is 1g/Kg-25g/Kg.
Preferable in above technical scheme, content of the OPO in milk powder is
24g/Kg-96g/Kg。
It is preferable in above technical scheme, in the milk albumin peptide or sheep whey protein peptide:Molecular weight is less than 1000
It is 75%-85% that the component of dalton, which accounts for total mass fraction,;The preparation method of the milk albumin peptide or sheep whey protein peptide
It is:It is raw material by bovine whey protein concentrate or sheep WPC, through enzyme hydrolysis, separates the lactalbumin peptide composition of acquisition,
Wherein:It is 75%-85% that molecular weight accounts for total mass fraction less than the peptide of 1000 dalton;By spray drying, bovine whey is produced
Protein peptides or sheep whey protein peptide.
It is preferable in above technical scheme, the water soluble vitamin premix, liposoluble vitamin premix and mineral
Within the scope of the content of matter premix meets national standard, and according to formula requirement addition.
It is as follows using the enhancing nutrient absorption of the present invention and the baby milk powder of immunity of organisms, effect:
(1) present invention is based on breast milk composition is studied, by adding human milk oligosaccharides (HMO), 1,3 two oleic acid 2- palms
Acid glycerol three ester (structured lipid OPO) and milk albumin peptide or sheep whey protein peptide, allow baby formula milk powder to be more nearly mother
Breast, help infant to maintain intestinal health state, and make nutrition preferably by infant's intestinal absorption.
(2) aliphatic acid plays critically important effect during infant growth, can be as main supply
The material of energy, structured lipid OPO are abbreviation of 1, the 3- positions containing the triglycerides of 2 oleic acid, 2- positions containing 1 palmitic acid, and it is more easy to
In digesting and assimilating for aliphatic acid and calcium nutriment, constipation is reduced, mitigates enteron aisle burden, health environment is built for enteron aisle.
(3) human milk oligosaccharides can be advantageous to the breeding of beneficial bacterium in enteron aisle, and suppressing harmful bacteria, (including streptococcus pneumonia exists
Interior a variety of harmful bacterias), prevent the enteron aisle of pathogen from sticking, so as to reduce stomach inflammation and enterogastritis caused by bacterial infection
The incidence of disease of property disease, strengthen immunity.
(4) it is small that molecular weight is made using ox or sheep WPC as raw material in milk albumin peptide or sheep whey protein peptide
In the peptide of 1000 dalton, finally it is added in a manner of dry-mixed in formula, effect is:A, milk albumin peptide or sheep lactalbumin
Peptide can be directly entered blood circulation as protein source and be utilized by body;B, just enteron aisle can be repaired well in enteron aisle to be damaged
Cell, and rise in value beneficial to beneficial bacterium;C, the raising of enzymatic activity in enteron aisle can be induced, and then proposes the development of small intestine digestive function
Before, promote digesting and assimilating for nutriment.
(5) 1,3 two ester of oleic acid 2- palmitic acids three, human milk oligosaccharides and milk albumin peptides or sheep whey protein peptide
Add simultaneously, play collaboration facilitation, formula milk of the invention can both promote to digest and assimilate nutriment, beneficial
Intestinal health, it is beneficial to improve immunity of organisms again.
(6) present invention also added other nutriments, such as docosahexaenoic acid, arachidonic acid, vitamin premix
Expect (including water miscible and fat-soluble), mineral substance premix etc. so that enhancing nutrient absorption of the invention and immunity of organism
Nutrition in the baby milk powder of power is formed closer to breast milk, achieves preferable technique effect.
The second object of the present invention is the infant's milk for providing a kind of above-mentioned enhancing nutrient absorption and immunity of organisms
The preparation method of powder, comprises the following steps:
Step 1: dispensing:Skimmed milk power, desalted whey powder, lactose, WPC, oligomeric gala are weighed by proportioning
Sugar, FOS, human milk oligosaccharides, mineral substance premix, water soluble vitamin premix, taurine and l-cn, it is molten
It is in 40 DEG C -55 DEG C of water in 3-4 times of mixed material gross weight and temperature, is well mixed and obtains the first mixed material;
Either, the fresh milk that the skimmed milk power as needed for proportioning is made is subjected to pasteurize, degreasing is obtained after fractionation of fatty
Milk;Desalted whey powder, lactose, WPC, galactooligosaccharide, FOS, human milk oligosaccharides, ore deposit are weighed by proportioning
It is mixed that material premix, water soluble vitamin premix, taurine and l-cn are well mixed to obtain first with skim milk
Compound material;
Step 2: batch mixing homogeneous:Composite plant oil, the ester of 1,3 2 oleic acid 2- palmitic acids three, soybean phosphorus are weighed by proportioning
Fat, docosahexaenoic acid, arachidonic acid and liposoluble vitamin premix, put with the first mixed material obtained by step 1
Enter to carry out homogeneous in high pressure homogenizer to obtain the second mixed material;
Step 3: sterilization:Second mixed material obtained by step 2 is sterilized;
Step 4: concentration:The second mixed material after step 3 sterilizes is concentrated, obtains the 3rd mixture
Material;
Step 5: spray drying:3rd mixed material is spray-dried to obtain the 4th mixed material;
Step 6: fluidized bed drying:4th mixed material is subjected to fluidized bed drying and cooled down, obtains original washing powder material;
Step 7: batch mixing:Milk albumin peptide or sheep whey protein peptide and nucleotides are weighed by proportioning, adds the base
Stirred in powder material, produce the baby formula milk powder of enhancing nutrient absorption and immunity of organisms;
Either, the docosahexaenoic acid adds with arachidonic acid in step 2 without wet method, but in step
Formula requirement is pressed with dry-mixed work with the powder form of docosahexaenoic acid grease powder and arachidonic acid oil powder in rapid seven
Skill is added, wherein:The mass content of docosahexaenoic acid is 8-10% in docosahexaenoic acid grease powder, arachidonic acid
Arachidonic mass content is 8-10% in oil powder.
It is preferable in above technical scheme, in the step 1:The temperature of pasteurize is 70 DEG C -75 DEG C, pasteurize
Time be the 18-30 seconds;
In the step 2:Homogenizing temperature is 50 DEG C -72 DEG C, homogenization pressure 10-20MPa;
In the step 3:Sterilization temperature is 85 DEG C -95 DEG C, and sterilizing time is the 15-30 seconds;
In the step 4:Concentrated using double-effect falling film evaporator, the first effect vacuum is 30-42kPa, evaporation temperature
Spend for 70 DEG C -75 DEG C;Second effect vacuum is 60-70kPa, and evaporating temperature is 45 DEG C -52 DEG C;3rd mixed material is concentrated into
15-25 ° of B é (Baume degrees);This step is concentrated using multiple-effect falling film evaporator, to save the energy, is reached heat energy and is fully reclaimed
Purpose.
In the step 5:Pressure be 12-20MPa, EAT is 150 DEG C -190 DEG C and temperature of outgoing air is 70
It is spray-dried under the conditions of DEG C -90 DEG C;
In the step 7:Stirring uses three-dimensional dry-mixed machine, and mixing time is 15-20 minutes, reaches mixing intensity and adds up to
700-730 turns/batch, it is therefore an objective to mixes to than more uniform.
Using the preparation method of the present invention, have the following effects that:Processing step is simplified, and technological parameter is easily controlled, and is adapted to
The features such as large-scale production.
In addition to objects, features and advantages described above, the present invention also has other objects, features and advantages.
Below with reference to embodiment, the present invention is further detailed explanation.
Embodiment
Embodiments of the invention are described in detail below in conjunction with specific embodiment, but the present invention can be according to right
It is required that the multitude of different ways for limiting and covering is implemented.
Embodiment 1:
A kind of baby formula milk powder for strengthening nutrient absorption and immunity of organisms, raw material includes lactose in terms of parts by weight
31 parts, 18 parts of desalted whey powder, 19.7 parts of skimmed milk power, composite plant oily 16 parts, the ester of 1,3 2 oleic acid 2- palmitic acids three
2.4 parts, 5 parts of WPC, 2 parts of galactooligosaccharide, 3 parts of FOS, 0.01 part of milk albumin peptide, mineral matter premix
0.9 part of material, 1.0 parts of arachidonic acid, 0.1 part of human milk oligosaccharides, 0.3 part of soybean lecithin, 0.3 part of docosahexaenoic acid, water
0.2 part of soluble vitamin premix, 0.02 part of nucleotides, 0.03 part of liposoluble vitamin premix, 0.03 part of taurine and
0.01 part of l-cn.
The human milk oligosaccharides are by saliva base lacto-N-tetraose c, three rock algae base lacto-N-neotetraose I, single rock algae base breast
Six sugared I of sugar-N- and double six sugared b of rock algae base lactose-N- are according to 1:1:1:1 quality proportioning mixes.
The composite plant oil is by high oleic sunflower oil 30%, soybean oil 25%, coconut oil 30% and rapeseed oil
15% mixes (in terms of mass fraction);In the high oleic sunflower oil:The mass fraction that oleic acid accounts for total fatty acids is
80%.
The mineral substance premix is made up of the material mixture of following percentage by weight:Calcium carbonate 30%, potassium chloride 29%,
Magnesium sulfate 18%, sodium citrate 10%, tricalcium phosphate 10%, ferrous sulfate 2.2%, zinc sulfate 0.7%, copper sulphate
0.0811%th, manganese sulfate 0.01%, KI 0.007% and sodium selenite 0.0019%.
The water soluble vitamin premix is made up of the material mixture of following percentage by weight:L-AA sodium
50%th, Choline Chloride 24.9%, inositol 18%, niacinamide 3%, D-VB5 calcium 1.1%, Bio 1.1%, cyanocobalamin
0.8%th, thiamine hydrochloride 0.5%, puridoxine hydrochloride 0.3%, riboflavin 0.18% and folic acid 0.12%.
The liposoluble vitamin premix is made up of the material mixture of following percentage by weight:Dl- α-D-α-tocopherol acetate
61%th, axerophtholum aceticum 22%, Vitamin D3 12% and phytondione 5%.
The preparation method of the baby milk powder of above-mentioned enhancing nutrient absorption and immunity of organisms, specifically includes following steps:
Step 1: dispensing:It (is 72 DEG C in temperature that the fresh milk that the skimmed milk power as needed for proportioning is made is carried out into pasteurize
Under the conditions of sterilize 20 seconds), obtain skim milk after fractionation of fatty;Desalted whey powder, lactose, condensed whey egg are weighed by proportioning
In vain, galactooligosaccharide, FOS, human milk oligosaccharides, mineral substance premix, water soluble vitamin premix, taurine and
L-cn is well mixed to obtain the first mixed material with skim milk;
Step 2: batch mixing homogeneous:Composite plant oil, the ester of 1,3 2 oleic acid 2- palmitic acids three, 22 are weighed by proportioning
Carbon acid, arachidonic acid, soybean lecithin and liposoluble vitamin premix, put with the first mixed material obtained by step 1
Enter to carry out homogeneous in high pressure homogenizer to obtain the second mixed material;Wherein:Homogenizing temperature is 65 DEG C, homogenization pressure 15MPa;
Step 3: sterilization:Second mixed material obtained by step 2 is sterilized, wherein:Sterilization temperature is 85 DEG C, sterilization
Time is 15 seconds;
Step 4: concentration:The second mixed material after step 3 sterilizes is concentrated, obtains the 3rd mixture
Material;Wherein:Concentrated using double-effect falling film evaporator, the first effect vacuum is 39kPa, and evaporating temperature is 72 DEG C;Second effect
Vacuum is 68kPa, and evaporating temperature is 50 DEG C;3rd mixed material is concentrated into 18 ° of B é;
Step 5: spray drying:3rd mixed material is spray-dried to obtain the 4th spray drying powdery material, tool
Body is:Pressure is 16MPa, EAT is 170 DEG C and temperature of outgoing air be 85 DEG C under the conditions of be spray-dried;
Step 6: fluidized bed drying:4th spray drying powdery material is subjected to fluidized bed drying and cools down (control material
Middle water content is 3.0wt%), obtain original washing powder material;
Step 7: batch mixing:Milk albumin peptide and nucleotides are weighed by proportioning, adds in the original washing powder material and stirs
(stirring uses three-dimensional dry-mixed machine, and mixing time is 20 minutes), produce infant's milk of enhancing nutrient absorption and immunity of organisms
Powder.
The baby milk powder of above-mentioned enhancing nutrient absorption and immunity of organisms can also be packed, be specifically:Using
Vacuum nitrogen or carbon dioxide controlled atmospheric packing, form minimum sales unit product (such as canned or packed or other monomers packaging shape
The product of formula).
Above-mentioned enhancing nutrient absorption should meet national related to the testing result of the baby formula milk powder of immunity of organisms
Product standard requirement.
Embodiment 2:
A kind of baby milk powder for strengthening nutrient absorption and immunity of organisms, its difference from Example 1 are:Baby children
Youngster's milk powder raw material in terms of parts by weight includes following components:It is 25 parts of lactose, 18 parts of desalted whey powder, 25.59 parts of skimmed milk power, multiple
Close 16 parts of vegetable oil, 3.86 parts of 1,3 2 oleic acid 2- palmitic acids, three ester, 5 parts of WPC, galactooligosaccharide 0.05
Part, 0.05 part of FOS, 0.8 part of mineral substance premix, arachidonic acid oil powder (arachidonic acid ARA mass content
For 10%) 3 parts, 0.1 part of human milk oligosaccharides, 0.2 part of soybean lecithin, docosahexaenoic acid grease powder (docosahexaenoic acid
DHA mass content for 10%) 2 parts, 0.1 part of water soluble vitamin premix, milk albumin peptide 0.2,0.02 part of nucleotides,
0.01 part of 0.01 part of liposoluble vitamin premix, 0.01 part of taurine and l-cn.
2nd, the skimmed milk power in the present embodiment is finished product, without being made using fresh milk;The human milk oligosaccharides are lactose-N-
Newly the sugared, p- lactose-N- of double rock algae bases six new six is sugared by two rock algaes, six sugared IV, lactose-N-, lactose-N- new ten is sugared and three rock algaes
The sugar of base-iso- lactose-N- ten is according to 1:1:2:1:3 quality proportioning mixes.
3rd, the present embodiment vitamin, mineral matter proportioning are as follows:
The mineral substance premix is made up of the material mixture of following percentage by weight:Calcium carbonate 25%, potassium chloride 25%,
Magnesium sulfate 17%, sodium citrate 12%, tricalcium phosphate 18%, ferrous sulfate 2.2%, zinc sulfate 0.7%, copper sulphate 0.082%,
Manganese sulfate 0.01%, KI 0.007% and sodium selenite 0.001%.
The water soluble vitamin premix is made up of the material mixture of following percentage by weight:L-AA sodium
45%th, Choline Chloride 25.7%, inositol 20%, niacinamide 4.8%, D-VB5 calcium 1.8%, Bio 1%, cyanocobalamin
0.5%th, thiamine hydrochloride 0.5%, puridoxine hydrochloride 0.5%, riboflavin 0.05% and folic acid 0.15%.
The liposoluble vitamin premix is made up of the material mixture of following percentage by weight:Dl- α-D-α-tocopherol acetate
70%th, axerophtholum aceticum 15%, Vitamin D3 7% and phytondione 8%.
4th, docosahexaenoic acid and arachidonic acid add in step 2 without wet method, but with two in step 7
Dodecahexaene acid lipid powder (docosahexaenoic acid DHA mass contents are 10%), arachidonic acid oil powder (arachidonic
Sour ARA mass contents are added for powder form 10%) by formula requirement with dry mixing process.
The testing result of the above-mentioned enhancing nutrient absorption of detection of the present embodiment milk powder and the baby milk powder of immunity of organisms
National products standards requirement should be met, and performance is close with embodiment 1.
Embodiment 3:
A kind of baby milk powder for strengthening nutrient absorption and immunity of organisms, its difference from Example 1 are:
Baby milk powder raw material in terms of parts by weight includes following components:28 parts of lactose, 20 parts of desalted whey powder, defatted milk
14.4 parts of powder, 16 parts of composite plant oil, 9.6 parts of 1,3 2 oleic acid 2- palmitic acids, three ester, 5 parts of WPC, sheep whey
0.1 part of protein peptides, 0.05 part of galactooligosaccharide, 0.98 part of FOS, 1.0 parts of mineral substance premix, arachidonic acid 1.2
Part, 1.7 parts of human milk oligosaccharides, 1.2 parts of soybean lecithin, 0.2 part of docosahexaenoic acid, 0.4 part of water soluble vitamin premix,
0.02 part of 0.05 part of nucleotides, 0.06 part of liposoluble vitamin premix, 0.04 part of taurine and l-cn.
2nd, the human milk oligosaccharides are that 6'- salivas base-N- acetylation lactose amine and three rock algae base lacto-N-neotetraose I are pressed
According to 1:4 quality proportioning mixes.
3rd, the present embodiment vitamin, mineral matter proportioning are as follows:
The mineral substance premix is made up of the material mixture of following percentage by weight:Calcium carbonate 28%, potassium chloride 28%,
Magnesium sulfate 20%, sodium citrate 12.2%, tricalcium phosphate 9%, ferrous sulfate 1.8%, zinc sulfate 0.8%, copper sulphate
0.135%th, manganese sulfate 0.05%, KI 0.012% and sodium selenite 0.003%.
The water soluble vitamin premix is made up of the material mixture of following percentage by weight:L-AA sodium
49.1%th, Choline Chloride 26%, inositol 18%, niacinamide 3%, D-VB5 calcium 1%, Bio 1%, cyanocobalamin 0.6%, salt
Allithiamine element 0.45%, puridoxine hydrochloride 0.45%, riboflavin 0.1% and folic acid 0.3%.
The liposoluble vitamin premix is made up of the material mixture of following percentage by weight:Dl- α-D-α-tocopherol acetate
60%th, axerophtholum aceticum 20%, Vitamin D3 12% and phytondione 8%.
The testing result of humanized milk powder obtained by the present embodiment meets relevant national standard requirement, and performance and embodiment 1
It is close.
Comparative example 1:
The baby formula milk powder difference from Example 1 of this comparative example is:Without human milk oligosaccharides;Degreasing
Milk powder dosage is 19.8 parts.
Comparative example 2:
The baby formula milk powder difference from Example 2 of this comparative example is:Without 1,3 2 oleic acid 2- palms
Acid glycerol three ester and human milk oligosaccharides;Skimmed milk power dosage is 29.55 parts.
The oleic acid of 1,3- bis- (is free of using embodiment 1-3, comparative example 1-2 and prior art baby formula milk powder
The ester of 2- palmitic acids three, human milk oligosaccharides and milk albumin peptide or sheep whey protein peptide) tested:
1st, subjects:SPF level health male SD rat (14 age in days), 29.39 ± 1.89g of average weight.
2nd, test method:The experiment of rat is fed using different formulations milk powder, measures rat production performance and nutriment
Digestibility, it is specifically:
2.1st, 14 age in days rats are randomly divided into six groups by body weight, every group 16, feed baby children obtained by embodiment 1-3 respectively
Youngster's formula milk (experimental group 1-3), baby formula milk powder obtained by comparative example 1-2 (contrast experiment organizes 1-2) and existing
(blank group, it is oligomeric that signified blank group is free from OPO, human milk to the baby milk powder of technology
Sugar, the baby milk powder of milk albumin peptide (or sheep whey protein peptide).During experiment, each group animal presses rat nutritional need mark
Standard, quantitative bowel lavage, quantitative water compensating early stage (before 21 days), later stage free water (after 21 days), five weeks test periods.
For measuring the mouse of blood calcium, then eye socket takes blood in 3 minutes after last is fed.
2.2nd, Testing index and method, it is specifically:National feed industry mark is respectively adopted in crude protein, crude fat, aliphatic acid
The GB/T 6432-1994 of Zhun Hua technical committees customization, GB/T 6433-2006, GB/T 21514-2008 methods;Blood calcium contains
Measurement is pressed surveys serum calcium levels with EDTA titrations;Measurement data is represented with average ± standard deviation, soft using SPSS18.00
Part bag carries out data processing.Experimental result is analyzed using single factor test variance.With p≤0.05, mean difference has conspicuousness, has
Statistical significance.
3rd, result of the test, Details as Follows (X represents average value, behalf amplitude):
3.1st, to the influence of rat production performance, table 1 is referred to:
Influence statistical form (X ± s) of the 1 each formula milk of table to rat production performance
Group/parameter | Average daily gain (g) | Feedstuff-meat ratio |
Blank group | 3.64±0.85 | 1.45±0.32 |
Experimental group 1 | 6.33±0.15 | 2.25±0.41 |
Experimental group 2 | 6.0±0.12 | 2.85±0.45 |
Experimental group 3 | 6.12±0.17 | 2.55±0.12 |
Contrast experiment's group 1 | 5.94±0.15 | 2.21±0.07 |
Contrast experiment's group 2 | 5.93±0.12 | 2.20±0.96 |
It can be seen from table 1:
Analysis of variance and multiple comparative test, between blank group and experimental group, between blank group and contrast experiment's group with
And having significant difference between experimental group and contrast experiment's group, contrast experiment organizes between 1-2 and equal nothing between experimental group 1-3
Significant difference, illustrate problems with:(1) blank group, experimental group and contrast experiment's group can be sent out for the growth of mouse well
Nutrition needed for offer is provided;(2) it is a kind of in addition human milk oligosaccharides, structured lipid OPO and milk albumin peptide or sheep whey protein peptide
Or several can mouse growth be promoted to develop;(3) using human milk oligosaccharides, structured lipid OPO and the milk albumin peptide of the present invention
Or the technical scheme of sheep whey protein peptide triplicity, positive effect are better than prior art (blank group) and single use scheme
(contrast experiment organizes 1-2), it is seen that the combination of three achieves unexpected effect.
3.2nd, to the influence of the nutritive digestibility of rat, table 2 is referred to:
The calculation formula of nutritive digestibility is as follows:Nutrient apparent digestibility %=(is sought in nutrient intake-excrement
Foster plain just content)/nutrient intake × 100%.
Influence statistical form (X ± s) of the 2 each formula milk of table to rat nutritive digestibility
Group/parameter | Crude protein (%) | Crude fat (%) | Aliphatic acid (%) |
Blank group | 82.12±0.88 | 85.33±0.12 | 79.22±0.3 |
Experimental group 1 | 92.15±0.80 | 93.45±0.12 | 93.12±0.51 |
Experimental group 2 | 93.27±0.66 | 94.10±0.1 | 94.32±0.31 |
Experimental group 3 | 91.05±0.03 | 94.25±0.17 | 93.2±0.5 |
Contrast experiment's group 1 | 85.16±0.44 | 88.14±0.15 | 87.14±0.4 |
Contrast experiment's group 2 | 84.11±0.12 | 85.24±0.2 | 86.3±0.44 |
It can be seen from table 2:
Analysis of variance and multiple comparative test, between blank group and experimental group, between blank group and contrast experiment's group with
And having significant difference between experimental group and contrast experiment's group, contrast experiment organizes between 1-2 and equal nothing between experimental group 1-3
Significant difference, illustrate problems with:The crude protein, crude fat and aliphatic acid apparent digestibility that blank group feeds mouse are substantially low
In experimental group and contrast experiment's group, and contrast experiment organizes each nutrient digestibility and is significantly lower than experimental group, it is possible thereby to illustrate,
The combination of human milk oligosaccharides, structured lipid OPO and milk albumin peptide or sheep whey protein peptide three are improved and promoted well
The digestion and absorption of above nutrient.
3.3rd, to the influence of the blood parameters of rat, Details as Follows:
(1) to the influence of the blood calcium of rat, table 3 is referred to:
Influence statistical form (X ± s) of the 3 each formula milk of table to rat blood calcium
Group/parameter | Blood calcium (mmol/L) |
Blank group | 1.33±0.03 |
Experimental group 1 | 2.23±0.34 |
Experimental group 2 | 2.10±0.84 |
Experimental group 3 | 2.22±0.1 |
Contrast experiment's group 1 | 2.0±0.34 |
Contrast experiment's group 2 | 1.98±0.34 |
It can be seen from table 3:
Analysis of variance and multiple comparative test, hence it is evident that blank group feed mouse blood calcium concentration be substantially lower than experimental group and
Contrast experiment's group;And contrast experiment's group is less than experimental group.It fact proved that experimental group nursing mouse can preferably play to assimilate food
In calcium.
By contrasting blank group, experimental group and contrast experiment's group it is known that blank group Nutrients Absorption is worst, experimental group
Most preferably.It is possible thereby to illustrate, the milk powder of this formula can play a part of strengthening Nutrients Absorption.
(2) to the influence of the routine blood indexes of rat, it is specifically:Blood, cellanalyzer zootype are taken through femoral artery
Pre-dilution method determines 19 physical signs of rat blood, leucocyte WBC, neutrophil leucocyte Neu, lymphocyte Lym, intermediate value cell
Mid, neutrophil leucocyte percentage Neu%, lymphocyte percentage Lym%, intermediate value cell percentages Mid%;Red blood cell RBC,
Hemoglobin concentration Hb, packed cell volume HCT, mean corpuscular volume (MCV) MCV, mean corpuscular hemoglobin MCH are average red thin
Extracellular hemoglobin concentration MCHC, RDW coefficient of variation RDW-CV, RDW standard deviation
RDW-SD;Number of platelets PLT, mean platelet volume MPV, MPW PDW, thrombocytocrit PCT.Refer to table
4th, table 5 and table 6:
Influence statistical form (X ± s) of the 4 each formula milk of table to rat routine blood indexes 1
Influence statistical form (X ± s) spss of 5 each formula milk of table to rat routine blood indexes 2
Influence statistical form (X ± s) of the 6 each formula milk of table to rat routine blood indexes 3
Group/parameter | N | PLT(×109/L) | MPV(fL) | PDW (%) | PCT (%) |
Blank group | 10 | 650.25±120.50 | 7.68±0.55 | 15.75±0.21 | 0.65±0.21 |
Experimental group 1 | 10 | 714.65±155.13 | 6.89±0.56 | 16.45±1.32 | 0.58±0.13 |
Experimental group 2 | 10 | 952.10±152.32 | 7.85±0.21 | 15.42±0.10 | 0.71±0.11 |
Experimental group 3 | 10 | 758.11±163.12 | 8.41±1.23 | 16.32±0.15 | 0.60±0.32 |
Contrast experiment's group 1 | 10 | 749.68±14.65 | 7.66±1.56 | 18.65±1.23 | 0.68±0.21 |
Contrast experiment's group 2 | 10 | 801.56±16.89 | 7.19±0.29 | 17.65±1.05 | 0.67±0.11 |
(3) to the influence of the trilute (T3), thyroxine (T4) of rat, table 7 is referred to:
Influence statistical form (X ± s) of the 7 each formula milk of table to the T3 and T4 of rat
Group/parameter | N | T3 | T4 |
Blank group | 10 | 0.55±0.08 | 40.05±1.63 |
Experimental group 1 | 10 | 1.28±0.12 | 59.12±5.41 |
Experimental group 2 | 10 | 1.24±0.44 | 62.47±4.12 |
Experimental group 3 | 10 | 2.01±0.40 | 60.71±6.73 |
Contrast experiment's group 1 | 10 | 0.81±0.11 | 41.81±3.47 |
Contrast experiment's group 2 | 10 | 0.97±0.10 | 44.74±2.14 |
Analysis of variance and multiple comparative test, experimental group and blank group, contrast experiment organize contrast, RBC in rat blood,
Hb, HCT, MCV, MCH significantly increase, and have statistical significance;The horizontal obvious reductions of RDW-CV.On the basis of more than, enter one
Step carries out general pathologic examination discovery:
Liver:All murine liver tissue structural integrities, lobuli hepatis fall through substantially, and with being normally no different.
Kidney:Envelope is complete, there is dense connective tissue composition;Envelope hypopallium is multiple to be dispersed in glomerulus, clear in structure;Kidney
Tubular epithelial aligned orderly, it is uniform in size, show no obvious abnormalities.
Duodenum:Clear in structure, fine hair is complete, marshalling, and lamina propria is without congestion and edema, blank group and contrast experiment
Group mouse duodenal section has no obvious cell infiltration.But the visible goblet cell of mouse duodenal of experimental group increases.
The mucus of goblet cell secretion has protection and a mucosedative effect, its quantity number reflect the health status of intestinal mucosa,
It is the abnormal sensitive instruction of intestinal mucosal, goblet cell increases prompting mucous membrane of small intestine immunologic function and improved.
In summary, compared with blank group and contrast experiment's group, the effect of experimental group is:(1) it can more promote body blood red
Albumen increases, and T3 and T4 levels improve, and goblet cell increases, and enhances immunity of organisms;(2) can more increase
Nutrients Absorption and raising immunity of organisms.
The preferred embodiments of the present invention are the foregoing is only, are not intended to limit the invention, for the skill of this area
For art personnel, the present invention can have various modifications and variations.Within the spirit and principles of the invention, that is made any repaiies
Change, equivalent substitution, improvement etc., should be included in the scope of the protection.
Claims (8)
- A kind of 1. baby milk powder for strengthening nutrient absorption and immunity of organisms, it is characterised in that the raw material bag in terms of parts by weight Include following components:Lactose 25-33 parts, desalted whey powder 15-20 parts, skimmed milk power 12-37 parts, composite plant oil 16-27 parts, 1, The ester 2.4-9.6 parts of 3 two oleic acid 2- palmitic acids three, WPC 5-9 parts, galactooligosaccharide 0-6 parts, FOS 0- 6 parts, milk albumin peptide or sheep whey protein peptide 0.01-0.3 parts, mineral substance premix 0.8-1.5 parts, arachidonic acid 0.3- 1.8 parts, human milk oligosaccharides 0.1-2.5 parts, soybean lecithin 0.2-1.2 parts, docosahexaenoic acid 0.2-1.0 parts, water soluble vitamin Raw plain premix 0.1-0.4 parts, nucleotides 0.018-0.05 parts, liposoluble vitamin premix 0.01-0.06 parts, taurine 0.01-0.04 parts and l-cn 0.01-0.02 parts;Each component parts by weight sum is 100 parts.
- A kind of 2. baby milk powder for strengthening nutrient absorption and immunity of organisms according to claim 1, it is characterised in that The human milk oligosaccharides are 2'- rock algae bases lactose, 3- rock algae bases lactose, 3'- salivas lactose, 3'- saliva base-N- acetyl lactose Amine, 6'- salivas lactose, 6'- saliva base-N- acetylation lactose amine, 3'- saliva base -3- rock algae bases lactose, two sialyllactoses, Single rock algae base, single saliva base lactose, lactose-N- trisaccharides, lacto-N-tetraose, lacto-N-neotetraose, saliva base lacto-N-tetraose A, saliva base lacto-N-tetraose b, saliva base lacto-N-tetraose c, saliva base lacto-N-tetraose d, double saliva base lactose-N- four Sugar, lactose-bis- rocks algae tetrose, single saliva base, single rock algae base lacto-N-tetraose, single saliva base, single rock algae base lactose-N- new four Sugar, three rock algae base lacto-N-neotetraose I, lactose-N- rock algae pentasaccharides I, lactose-N- rock algae pentasaccharides II, lactose-N- rock algae pentasaccharides III, lactose-N- rock algae pentasaccharides VI, lactose-N- rock algae pentasaccharides V, saliva base-lactose-N- rock algae pentasaccharides V, the new rock algaes of lactose-N- Pentasaccharides I, lactose-N- six are sugared, p- lactose-N- six is sugared, lactose-N- new six is sugared, rock algae base-p- lactose-N- six is sugared, double rock algaes Base-p- lactose-N- six is sugared, sugared, the single rock algae base lactose-N- of single sugared, single rock algae base lactose-N- six of saliva base-lactose-N- new six Six sugared I, single six sugared III of rock algae base lactose-N-, double six sugared a of rock algae base lactose-N-, double six sugared b of rock algae base lactose-N-, double rock algaes Sugared, the double new six sugared b of rock algae base lactose-N- of six sugared c of base lactose-N-, double rock algae base lactose-N- new six, double rock algae base-p- lactose- N- six is sugared, single saliva base, and new six sugar of double new six sugared, double rock algae base-p- lactose-N- of rock algae base lactose-N-, three rock algae base lactose- The sugar of N- six, the sugar of three rock algae bases-p- lactose-N- six, two rock algaes of lactose-N-, six sugared I, two rock algaes of lactose-N-, six sugared II, lactose-N- Two rock algaes, six sugared IV, lactose-N- newly the sugar of double rock algae bases six, lactose-N- newly new six sugar of double six sugared II of rock algae base, p- lactose-N-, At least one of new ten sugar of lactose-N- and three rock algae bases-sugar of iso- lactose-N- ten.
- 3. the baby milk powder of a kind of enhancing nutrient absorption and immunity of organisms according to claim 1-2 any one, Characterized in that, content of the human milk oligosaccharides in milk powder is 1g/Kg-25g/Kg.
- A kind of 4. baby milk powder for strengthening nutrient absorption and immunity of organisms according to claim 3, it is characterised in that Content of the ester of bis- oleic acid 2- palmitic acids of 1,3- three in milk powder is 24g/Kg-96g/Kg.
- A kind of 5. baby milk powder for strengthening nutrient absorption and immunity of organisms according to claim 3, it is characterised in that In the milk albumin peptide or sheep whey protein peptide:Molecular weight accounts for total mass fraction less than the component of 1000 dalton 75%-85%;The preparation method of the milk albumin peptide or sheep whey protein peptide is:By bovine whey protein concentrate or sheep whey Protein concentrate is raw material, through enzyme hydrolysis, separates the lactalbumin peptide composition of acquisition, wherein:Molecular weight is less than 1000 dalton It is 75%-85% that peptide composition, which accounts for total mass fraction,;By spray drying, milk albumin peptide or sheep whey protein peptide are produced.
- A kind of 6. baby milk powder for strengthening nutrient absorption and immunity of organisms according to claim 3, it is characterised in that The content of the water soluble vitamin premix, liposoluble vitamin premix and mineral substance premix meet national standard scope it It is interior.
- A kind of 7. system of the baby milk powder of enhancing nutrient absorption as claimed in any one of claims 1 to 6 and immunity of organisms Make method, it is characterised in that comprise the following steps:Step 1: dispensing:Skimmed milk power, desalted whey powder, lactose, WPC, galactooligosaccharide, low is weighed by proportioning Fructooligosaccharides, human milk oligosaccharides, mineral substance premix, water soluble vitamin premix, taurine and l-cn, are dissolved in mixing 3-4 times of material gross weight and temperature are in 40 DEG C -55 DEG C of water, are well mixed and obtain the first mixed material;Either, the fresh milk that the skimmed milk power as needed for proportioning is made is subjected to pasteurize, skim milk is obtained after fractionation of fatty; Desalted whey powder, lactose, WPC, galactooligosaccharide, FOS, human milk oligosaccharides, mineral matter are weighed by proportioning Premix, water soluble vitamin premix, taurine and l-cn are well mixed to obtain the first mixture with skim milk Material;Step 2: batch mixing homogeneous:By proportioning weigh composite plant oil, the ester of 1,3 2 oleic acid 2- palmitic acids three, soybean lecithin, Docosahexaenoic acid, arachidonic acid and liposoluble vitamin premix, it is put into the first mixed material obtained by step 1 Homogeneous is carried out in high pressure homogenizer and obtains the second mixed material;Step 3: sterilization:Second mixed material obtained by step 2 is sterilized;Step 4: concentration:The second mixed material after step 3 sterilizes is concentrated, obtains the 3rd mixed material;Step 5: spray drying:3rd mixed material is spray-dried to obtain the 4th mixed material;Step 6: fluidized bed drying:4th mixed material is subjected to fluidized bed drying and cooled down, obtains original washing powder material;Step 7: batch mixing:Milk albumin peptide or sheep whey protein peptide and nucleotides are weighed by proportioning, adds the original washing powder thing Stirred in material, produce the baby formula milk powder of enhancing nutrient absorption and immunity of organisms;Either, the docosahexaenoic acid adds with arachidonic acid in step 2 without wet method, but in step 7 In with the powder form of docosahexaenoic acid grease powder and arachidonic acid oil powder by formula requirement added with dry mixing process Add, wherein:The mass content of docosahexaenoic acid is 8-10% in docosahexaenoic acid grease powder, arachidonic acid oil Arachidonic mass content is 8-10% in powder.
- 8. preparation method according to claim 7, it is characterised in thatIn the step 1:The temperature of pasteurize is 70 DEG C -75 DEG C, and the time of pasteurize is the 18-30 seconds;In the step 2:Homogenizing temperature is 50 DEG C -72 DEG C, homogenization pressure 10-20MPa;In the step 3:Sterilization temperature is 85 DEG C -95 DEG C, and sterilizing time is the 15-30 seconds;In the step 4:Concentrated using double-effect falling film evaporator, the first effect vacuum is 30-42kPa, and evaporating temperature is 70℃-75℃;Second effect vacuum is 60-70kPa, and evaporating temperature is 45 DEG C -52 DEG C;3rd mixed material is concentrated into 15-25 Baume degrees;In the step 5:Pressure is 12-20MPa, EAT is 150 DEG C -190 DEG C and temperature of outgoing air be 70 DEG C - It is spray-dried under the conditions of 90 DEG C;In the step 7:Stirring uses three-dimensional dry-mixed machine, and mixing time is 15-20 minutes, reaches mixing intensity and adds up to 700- 730 turns/batch, it is well mixed.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710687015.3A CN107347998A (en) | 2017-08-11 | 2017-08-11 | A kind of baby milk powder for strengthening nutrient absorption and immunity of organisms and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710687015.3A CN107347998A (en) | 2017-08-11 | 2017-08-11 | A kind of baby milk powder for strengthening nutrient absorption and immunity of organisms and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107347998A true CN107347998A (en) | 2017-11-17 |
Family
ID=60288215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710687015.3A Pending CN107347998A (en) | 2017-08-11 | 2017-08-11 | A kind of baby milk powder for strengthening nutrient absorption and immunity of organisms and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107347998A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108244249A (en) * | 2018-01-16 | 2018-07-06 | 广州市美素力营养品有限公司 | A kind of babies ' formula milk powder and preparation method |
CN110074209A (en) * | 2019-05-16 | 2019-08-02 | 福建农林大学 | A kind of baby formula milk powder and preparation method thereof containing human milk oligosaccharides and lactoferrin |
CN110122865A (en) * | 2019-06-03 | 2019-08-16 | 哈尔滨工业大学 | A kind of supplementary food for infants and preparation method thereof adding breast milk oligosaccharide |
CN110651830A (en) * | 2019-09-29 | 2020-01-07 | 澳优乳业(中国)有限公司 | Modified milk powder for improving sleep and preparation method thereof |
CN112335889A (en) * | 2020-09-30 | 2021-02-09 | 营家健康科技(广东)有限公司 | Compound protein powder for improving human immunity in multiple levels and preparation method thereof |
CN115053928A (en) * | 2022-06-27 | 2022-09-16 | 北京精培医学研究院 | Milk powder replacing milk for newborn and preparation method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102283289A (en) * | 2011-09-15 | 2011-12-21 | 澳优乳业(中国)有限公司 | Anti-inflaming infant formula milk powder and preparation process thereof |
WO2013056038A2 (en) * | 2011-10-14 | 2013-04-18 | Abbott Laboratories | Sterilized liquid protein supplement |
CN104351356A (en) * | 2014-11-25 | 2015-02-18 | 澳优乳业(中国)有限公司 | Novel fourth-generation infant formula and preparation method thereof |
CN105532883A (en) * | 2015-12-21 | 2016-05-04 | 海普诺凯营养品有限公司 | Formula goat milk powder for infants and young children and preparation method thereof |
CN106343029A (en) * | 2016-08-26 | 2017-01-25 | 黑龙江飞鹤乳业有限公司 | Infant formula for improving intestinal absorption and comfort and preparing method thereof |
-
2017
- 2017-08-11 CN CN201710687015.3A patent/CN107347998A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102283289A (en) * | 2011-09-15 | 2011-12-21 | 澳优乳业(中国)有限公司 | Anti-inflaming infant formula milk powder and preparation process thereof |
WO2013056038A2 (en) * | 2011-10-14 | 2013-04-18 | Abbott Laboratories | Sterilized liquid protein supplement |
CN104351356A (en) * | 2014-11-25 | 2015-02-18 | 澳优乳业(中国)有限公司 | Novel fourth-generation infant formula and preparation method thereof |
CN105532883A (en) * | 2015-12-21 | 2016-05-04 | 海普诺凯营养品有限公司 | Formula goat milk powder for infants and young children and preparation method thereof |
CN106343029A (en) * | 2016-08-26 | 2017-01-25 | 黑龙江飞鹤乳业有限公司 | Infant formula for improving intestinal absorption and comfort and preparing method thereof |
Non-Patent Citations (1)
Title |
---|
陈栋梁: "《多肽的世界:认识功能肽》", 31 October 2003, 武汉出版社 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108244249A (en) * | 2018-01-16 | 2018-07-06 | 广州市美素力营养品有限公司 | A kind of babies ' formula milk powder and preparation method |
CN110074209A (en) * | 2019-05-16 | 2019-08-02 | 福建农林大学 | A kind of baby formula milk powder and preparation method thereof containing human milk oligosaccharides and lactoferrin |
CN110122865A (en) * | 2019-06-03 | 2019-08-16 | 哈尔滨工业大学 | A kind of supplementary food for infants and preparation method thereof adding breast milk oligosaccharide |
CN110122865B (en) * | 2019-06-03 | 2022-02-08 | 哈尔滨工业大学 | Infant auxiliary food added with breast milk oligosaccharide and preparation method thereof |
CN110651830A (en) * | 2019-09-29 | 2020-01-07 | 澳优乳业(中国)有限公司 | Modified milk powder for improving sleep and preparation method thereof |
CN110651830B (en) * | 2019-09-29 | 2023-03-24 | 澳优乳业(中国)有限公司 | Modified milk powder for improving sleep and preparation method thereof |
CN112335889A (en) * | 2020-09-30 | 2021-02-09 | 营家健康科技(广东)有限公司 | Compound protein powder for improving human immunity in multiple levels and preparation method thereof |
CN115053928A (en) * | 2022-06-27 | 2022-09-16 | 北京精培医学研究院 | Milk powder replacing milk for newborn and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107347998A (en) | A kind of baby milk powder for strengthening nutrient absorption and immunity of organisms and preparation method thereof | |
JP4755762B2 (en) | Powdered human milk fortifier | |
AU2010203123B2 (en) | Infant formula containing nucleotides | |
EP2592938B2 (en) | Dairy product and process | |
CN104351356A (en) | Novel fourth-generation infant formula and preparation method thereof | |
CN105994680A (en) | Infant formula goat milk powder and preparation method thereof | |
CN105188409A (en) | Infant nutritional product with RRR alpha-tocopherol | |
CN103070242A (en) | Formula goat milk powder for pregnant women and preparation method of formula goat milk powder | |
RU2703177C2 (en) | Infant nutrition with hydrolysed protein, ionic calcium and palmitic acid | |
CN111345352A (en) | Contains vitamin K2Children's formula milk powder of yak milk mixed with sialic acid and preparation method | |
RU2703172C2 (en) | Feeding for infants with hydrolysed protein and palmitic acid | |
CN1066917C (en) | Milk product enriched with ground eggshell | |
EP0814668B1 (en) | Process for producing foods for premature babies and infants and dietetic foods | |
Swensson et al. | The prospect of obtaining beneficial mineral and vitamin contents in cow’s milk through feed | |
JP3203485B2 (en) | Infant food composition with adjusted phospholipid and fatty acid composition | |
CN110200086A (en) | A kind of fat or oil composition | |
Sánchez-Hidalgo et al. | A fortifier comprising protein, vitamins, and calcium-glycerophosphate for preterm human milk | |
Linfesty | Nutrient Analysis of Water Buffalo Milk and Water Buffalo Milk Acid Whey: a Pilot Study to Evaluate Suitability as a Protein Supplement for Human Consumption in Lao PDR: A Thesis | |
Vilas | Calcium availability in specific foods: Milk and dairy products, legumes, vegetables, cereals, baked goods and cooked meals | |
Kashyap | Ankit Kashyap, AK Santra, OP Dinani, Nishma Singh, Rupal Pahak, Subhrajit Das and Anupam Soni | |
CN114176137A (en) | Infant milk powder with high whey protein content and preparation method thereof | |
Eichelberger | The Importance of Economical Milk in Human Nutrition | |
CN108935706A (en) | A kind of nutrition is comprehensive and the babies ' formula milk powder and preparation method thereof of absorption easy to digest |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171117 |